FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 370 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway... September 16, 2020 FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma... April 11, 2025 The incredible value of going public November 22, 2021 EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 Load more HOT NEWS Black Women Have Nearly Three Times the Risk of Developing Triple... Moxetumomab Approved by FDA for Hairy Cell Leukemia Breast Cancer Survivors Are Still Underrepresented At Victoria’s Secret News digest – smoking ban, HPV and prostate cancer, genetic testing...
